Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments
暂无分享,去创建一个
[1] J. Noseworthy,et al. The impact of blinding on the results of a randomized, placebo‐controlled multiple sclerosis clinical trial , 1994, Neurology.
[2] A D Oxman,et al. Randomisation to protect against selection bias in healthcare trials. , 2011, The Cochrane database of systematic reviews.
[3] J. Montaner,et al. Recommendations guide for experimental animal models in stroke research. , 2011, Neurologia.
[4] Andrew S.C. Rice,et al. Animal models and the prediction of efficacy in clinical trials of analgesic drugs: A critical appraisal and call for uniform reporting standards , 2008, PAIN.
[5] R. Virmani,et al. Drug-Eluting Stents in Preclinical Studies: Updated Consensus Recommendations for Preclinical Evaluation , 2008, Circulation. Cardiovascular interventions.
[6] L. Ferguson,et al. The 10 basic requirements for a scientific paper reporting antioxidant, antimutagenic or anticarcinogenic potential of test substances in in vitro experiments and animal studies in vivo. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[7] N. Pullen,et al. The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies. , 2011, Human reproduction update.
[8] C. Begley,et al. Drug development: Raise standards for preclinical cancer research , 2012, Nature.
[9] Ulrich Dirnagl,et al. Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench , 2009, Stroke.
[10] F. Prinz,et al. Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.
[11] M. Macleod,et al. Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis. , 2011, Parkinsonism & related disorders.
[12] X. Montalban,et al. [Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis]. , 2012, Revista de neurología (Ed. impresa).
[13] U. Dirnagl,et al. Empirical Evidence of Bias in the Design of Experimental Stroke Studies: A Metaepidemiologic Approach , 2008, Stroke.
[14] S. Greenfield,et al. Clinical practice guidelines we can trust , 2011 .
[15] M. Emborg,et al. Beyond Access vs. Protection in Trials of Innovative Therapies , 2010, Science.
[16] G. Donnan,et al. 1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.
[17] R. Campbell,et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. , 1988, Cardiovascular research.
[18] R. Bolli,et al. Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy , 2004, Circulation research.
[19] H. Winn,et al. RODENT STROKE MODEL GUIDELINES FOR PRECLINICAL STROKE TRIALS (1ST EDITION). , 2009, Journal of experimental stroke & translational medicine.
[20] I. Cuthill,et al. Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals , 2009, PloS one.
[21] M. Stolina,et al. Rodent Preclinical Models for Developing Novel Antiarthritic Molecules: Comparative Biology and Preferred Methods for Evaluating Efficacy , 2010, Journal of biomedicine & biotechnology.
[22] W. Shadish,et al. Experimental and Quasi-Experimental Designs for Generalized Causal Inference , 2001 .
[23] Marc Fisher,et al. Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations , 2009, Stroke.
[24] M. Cases,et al. Inroads to Predict in Vivo Toxicology—An Introduction to the eTOX Project , 2012, International journal of molecular sciences.
[25] Nigel W. Hardy,et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project , 2008, Nature Biotechnology.
[26] M. Benatar,et al. Enhancing translation: Guidelines for standard pre-clinical experiments in mdx mice , 2012, Neuromuscular Disorders.
[27] J. Montaner,et al. Recommendations guide for experimental animal models in stroke research , 2011 .
[28] V. Steele,et al. Guidance for development of chemopreventive agents , 1994, Journal of cellular biochemistry. Supplement.
[29] D. Redelmeier,et al. Translation of research evidence from animals to humans. , 2006, JAMA.
[30] Michael Chopp,et al. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II , 2011, Stroke.
[31] L. Cronbach,et al. Designing evaluations of educational and social programs , 1983 .
[32] B. Reynolds. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): Bridging Basic and Clinical Science for Cellular and Neurogenic Factor Therapy in Treating Stroke , 2009, Stroke.
[33] Kimberly Scearce-Levie,et al. Animal Models of Alzheimer's Disease: Modeling Targets, Not Disease Accelerating Drug Discovery for Alzheimer's Disease: Best Practices for Preclinical Animal Studies , 2022 .
[34] M. Ashburner,et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration , 2007, Nature Biotechnology.
[35] Pedro Ramos-Cabrer,et al. Recommendations guide for experimental animal models in stroke research. , 2011, Neurologia.
[36] J. Menegazzi,et al. Drug administration in animal studies of cardiac arrest does not reflect human clinical experience. , 2007, Resuscitation.
[37] M. Brennan,et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. , 2005, Vaccine.
[38] B. Moreno,et al. Guía de uso adecuado de modelos animales para el desarrollo de terapias en esclerosis múltiple , 2012 .
[39] P. Bath,et al. Effects of NXY‐059 in experimental stroke: an individual animal meta‐analysis , 2009, British journal of pharmacology.
[40] G. Guyatt,et al. Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis* , 2010, Critical care medicine.
[41] Janet Woodcock,et al. The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.
[42] I. Cuthill,et al. Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .
[43] Albert C. Ludolph,et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[44] Susan Margulies,et al. Combination therapies for traumatic brain injury: prospective considerations. , 2009, Journal of neurotrauma.
[45] D. Howells,et al. Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy , 2010, PLoS biology.
[46] Rodney C. Samaco,et al. Preclinical research in Rett syndrome: setting the foundation for translational success , 2012, Disease Models & Mechanisms.
[47] Michelle E. Kho,et al. AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.
[48] M. Grounds,et al. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy , 2008, Neurobiology of Disease.
[49] D. Howells,et al. Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.
[50] S. Lazic,et al. A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.
[51] Iveta Simera,et al. EQUATOR: reporting guidelines for health research , 2008, Open medicine : a peer-reviewed, independent, open-access journal.
[52] J. E. Kranz,et al. Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[53] Alex J Sutton,et al. A Systematic Review of Systematic Reviews and Meta-Analyses of Animal Experiments with Guidelines for Reporting , 2006, Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes.
[54] Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.
[55] I. Cuthill,et al. Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.
[56] R. Bellomo,et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group , 2004, Critical care.
[57] J. Grimshaw,et al. North of England evidence based guidelines development project: methods of guideline development , 1996, BMJ.
[58] W J Sibbald,et al. Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis. , 1996, Critical care medicine.
[59] John P A Ioannidis,et al. Translation of highly promising basic science research into clinical applications. , 2003, The American journal of medicine.
[60] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[61] P. Lambiase,et al. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. , 2013, Pharmacology & therapeutics.
[62] Douglas G Altman,et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.
[63] James A. Anderson,et al. Should preclinical studies be registered? , 2012, Nature Biotechnology.